Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Kansal · SciRah

Researcher profile · Semantic Scholar

A. Kansal

Share profile

A. Kansal — researcher profile on SciRah

h-index: 26
Works: 105
Citations: 2,669

Most-cited papers

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
S. Sorensen, A. Kansal, S. Connolly, S. Peng +3 more
2011Thrombosis and Haemostasis221 citations
Semantic Scholar
Diversity of order and densities in jammed hard-particle packings.
A. Kansal, S. Torquato, F. Stillinger
2002Physical review. E, Statistical, nonlinear, and soft matter physics181 citations
Semantic Scholar
Computer generation of dense polydisperse sphere packings
A. Kansal, S. Torquato, F. Stillinger
2002166 citations
Semantic Scholar
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
A. Kansal, S. Sorensen, R. Gani, P. Robinson +3 more
2012Heart125 citations Open access
Semantic Scholar
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK
A. Hackshaw, Sarah S. Cohen, H. Reichert, A. Kansal +2 more
2021British Journal of Cancer72 citations Open access
Semantic Scholar
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada
A. Kansal, Michael Sharma, C. Bradley-Kennedy, A. Clemens +4 more
2012Thrombosis and Haemostasis65 citations
Semantic Scholar
Modeling Approaches to Type 2 Diabetes
A. Kansal
2004Diabetes Technology & Therapeutics46 citations
Semantic Scholar
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Ying Zheng, S. Sorensen, A. Gonschior, H. Noack +3 more
2014Clinical Therapeutics41 citations Open access
Semantic Scholar
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA
A. Tafazzoli, S. Ramsey, A. Shaul, Ameya Chavan +4 more
2022PharmacoEconomics (Auckland)40 citations Open access
Semantic Scholar
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG Outcome Trial.
O. Reifsnider, A. Kansal, C. Wanner, E. Pfarr +6 more
2021American Journal of Kidney Diseases40 citations Open access
Semantic Scholar
A Cellular Automaton Model of Brain Tumor Treatment and Resistance
Jonathan E. Schmitz, A. Kansal, S. Torquato
200240 citations Open access
Semantic Scholar
Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
A. Kansal, O. Reifsnider, I. Proskorovsky, Ying Zheng +4 more
2019Diabetic Medicine39 citations Open access
Semantic Scholar
Cost of cancer management by stage at diagnosis among Medicare beneficiaries
S. Reddy, M. Broder, E. Chang, C. Paydar +2 more
2022Current Medical Research and Opinion36 citations Open access
Semantic Scholar
Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests
H. Gelhorn, M. Ross, A. Kansal, E. Fung +3 more
2022Patient35 citations Open access
Semantic Scholar
Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
A. Kansal, M. Cowie, A. Kielhorn, S. Krotneva +3 more
2016Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease35 citations Open access
Semantic Scholar
Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design.
A. Kansal, J. Trimmer
2005Systems biology35 citations
Semantic Scholar
Health state utility values by cancer stage: a systematic literature review
Mir-Masoud Pourrahmat, A. Kim, A. Kansal, M. Hux +3 more
2021European Journal of Health Economics34 citations Open access
Semantic Scholar
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
A. Kansal, Ying Zheng, T. Pokora, S. Sorensen
2013Baillière's Best Practice & Research: Clinical Haematology30 citations
Semantic Scholar
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
Shi-En Guo, C. Pelligra, Catherine Saint-Laurent Thibault, L. Hernandez +1 more
2014PharmacoEconomics (Auckland)28 citations
Semantic Scholar
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial.
K. Kaku, M. Haneda, H. Sakamaki, A. Yasui +9 more
2019Clinical Therapeutics27 citations Open access
Semantic Scholar
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
O. Reifsnider, A. Kansal, P. Gandhi, L. Cragin +4 more
2021BMJ Open Diabetes Research & Care26 citations Open access
Semantic Scholar
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
O. Reifsnider, A. Kansal, P. Pimple, Valerie Aponte-Ribero +2 more
2020Diabetes, obesity and metabolism26 citations Open access
Semantic Scholar
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
W. Su, A. Kansal, C. Vicente, B. Deniz +1 more
2016Journal of Medical Economics26 citations Open access
Semantic Scholar
Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database
J. Hummel, R. Leipold, S. Amorosi, Haikun Bao +8 more
2019Cardiovascular Electrophysiology24 citations Open access
Semantic Scholar
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
A. Clemens, S. Peng, S. Brand, M. Brueckmann +5 more
2014American Journal of Cardiology23 citations Open access
Semantic Scholar
Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
O. Reifsnider, A. Kansal, J. Franke, Joseph Lee +8 more
2020ESC Heart Failure20 citations Open access
Semantic Scholar
Prediction of trapping rates in mixtures of partially absorbing spheres
A. Kansal, S. Torquato
200220 citations
Semantic Scholar
Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
A. Kansal, O. Reifsnider, S. Brand, N. Hawkins +6 more
2021Journal of Market Access & Health Policy17 citations Open access
Semantic Scholar
A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
S. Sorensen, S. Peng, B. Monz, C. Bradley-Kennedy +1 more
2013PharmacoEconomics (Auckland)15 citations Open access
Semantic Scholar
Globally and locally minimal weight spanning tree networks
A. Kansal, S. Torquato
200113 citations Open access
Semantic Scholar
Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data
I. Daacke, P. Kandaswamy, A. Tebboth, A. Kansal +1 more
201612 citations Open access
Semantic Scholar
Impact of early detection on cancer curability: A modified Delphi panel study
L. Schwartzberg, M. Broder, S. Ailawadhi, H. Beltran +11 more
2022PLoS ONE11 citations Open access
Semantic Scholar
Estimates of stage-specific preclinical sojourn time across 21 cancer types.
M. Broder, S. Ailawadhi, H. Beltran, L. Blakely +11 more
202110 citations
Semantic Scholar
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries
S. Peng, K. Deger, A. Ustyugova, P. Gandhi +3 more
2018Current Medical Research and Opinion10 citations
Semantic Scholar
Inclusion of compliance and persistence in economic models: past, present and future.
Ananth Kadambi, R. Leipold, A. Kansal, S. Sorensen +1 more
2012Applied Health Economics and Health Policy10 citations
Semantic Scholar
Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults With Cancer Diagnoses
D. Grabowski, A. Kansal, D. Goldman, D. Lakdawalla
2023JAMA Network Open9 citations Open access
Semantic Scholar
Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
T. Feldman, D. Zou, M. Rebeira, Joseph Lee +6 more
2020American Journal of Managed Care9 citations
Semantic Scholar
Impact of Empagliflozin (Jardiance) to the NHS: Estimation of Budget and Event Impact Based on Empa-Reg Outcome Data
I. Daacke, P. Kandaswamy, A. Tebboth, A. Kansal +1 more
20168 citations Open access
Semantic Scholar
[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
M. Monreal-Bosch, S. Soulard, C. Crespo, S. Brand +1 more
2017Revista de neurología (Ed. impresa)7 citations
Semantic Scholar
MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA
A. Kansal, Ying Zheng, I. Proskorovsky, S. Krotneva +2 more
20167 citations Open access
Semantic Scholar
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada
E. Dorman, A. Kansal, S. Sarda
2015Journal of Medical Economics7 citations Open access
Semantic Scholar
Cost–effectiveness of a FISH assay for the diagnosis of melanoma in the USA
A. Kansal, A. Shaul, S. Stern, K. Busam +2 more
2013Expert review of pharmacoeconomics & outcomes research7 citations
Semantic Scholar
Inclusion of Compliance and Persistence in Economic Models
Ananth Kadambi, R. Leipold, A. Kansal, S. Sorensen +1 more
2012Applied Health Economics and Health Policy7 citations
Semantic Scholar
Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)
A. Kansal, M. Du, O. Herrera-Restrepo, R. Leipold +3 more
20176 citations
Semantic Scholar
Modeling hard clinical end-point data in economic analyses
A. Kansal, Ying Zheng, R. Palencia, A. Ruffolo +2 more
2013Journal of Medical Economics6 citations
Semantic Scholar
Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada
D. Zou, Joseph Lee, A. Kansal, Wen-Qing Ma +4 more
2022Journal of Medical Economics5 citations Open access
Semantic Scholar
The Economic Impact of New Therapeutic Interventions on Neuropsychiatric Inventory (NPI) Symptom Scores in Patients with Alzheimer Disease
A. Tafazzoli, A. Kansal, P. Lockwood, Charles Petrie +1 more
2018Dementia and Geriatric Cognitive Disorders Extra4 citations Open access
Semantic Scholar
Abstract 17655: Cost-effectiveness of Ivabradine as a Treatment for Systolic Chronic Heart Failure in the United States
A. Kansal, M. Cowie, A. Kielhorn, S. Krotneva +3 more
20154 citations
Semantic Scholar
Economic modeling of new stent platforms to evaluate cost effectiveness: analysis of the TAXUS Liberté versus TAXUS express stents.
M. Turco, A. Kansal, S. Stern, S. Amorosi +3 more
2012Journal of interventional cardiology4 citations
Semantic Scholar
Cost-Effectiveness Analysis of Empagliflozin Compared with Canagliflozin or Standard of Care (SoC) in Patients with T2DM and Established Cardiovascular (CV) Disease
A. Kansal, O. Reifsnider, Joseph S. Lee, K. Fahrbach +3 more
2018Diabetes3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Sorensen×10
Invite
S. Sorensen — researcher profile on SciRah
O. Reifsnider×9
Invite
O. Reifsnider — researcher profile on SciRah
Ying Zheng×7
Invite
Ying Zheng — researcher profile on SciRah
S. Brand×7
Invite
S. Brand — researcher profile on SciRah

×5

Invite

S. Peng — researcher profile on SciRah

A. Ustyugova×5

Invite

A. Ustyugova — researcher profile on SciRah

Invite

S. Torquato — researcher profile on SciRah

Invite

E. Pfarr — researcher profile on SciRah

P. Kandaswamy×4

Invite

P. Kandaswamy — researcher profile on SciRah

Invite

R. Leipold — researcher profile on SciRah

C. Bradley-Kennedy×3

Invite

C. Bradley-Kennedy — researcher profile on SciRah

Invite

M. Cowie — researcher profile on SciRah